Functional repair of p53 mutation in colorectal cancer cells using trans-splicing
Metrics: PDF 1641 views | HTML 2256 views | ?
Xingxing He1,*, Jiazhi Liao1,*, Fang Liu2, Junwei Yan1, Jingjun Yan1, Haitao Shang3, Qian Dou3, Ying Chang1, Jusheng Lin1 and Yuhu Song3
1 Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
* These authors contributed equally to this work
Yuhu Song, email:
Jusheng Lin, email:
Keywords: colorectal cancer cells, mutant p53, trans-splicing
Received: September 30, 2014 Accepted: December 09, 2014 Published: December 10, 2014
Mutation in the p53 gene is arguably the most frequent type of gene-specific alterations in human cancers. Current p53-based gene therapy contains the administration of wt-p53 or the suppression of mutant p53 expression in p53-defective cancer cells. . We hypothesized that trans-splicing could be exploited as a tool for the correction of mutant p53 transcripts in p53-mutated human colorectal cancer (CRC) cells. In this study, the plasmids encoding p53 pre-trans-splicing molecules (PTM) were transfected into human CRC cells carrying p53 mutation. The plasmids carrying p53-PTM repaired mutant p53 transcripts in p53-mutated CRC cells, which resulted in a reduction in mutant p53 transcripts and an induction of wt-p53 simultaneously. Intratumoral administration of adenovirus vectors carrying p53 trans-splicing cassettes suppressed the growth of tumor xenografts. Repair of mutant p53 transcripts by trans-splicing induced cell-cycle arrest and apoptosis in p53-defective colorectal cancer cells in vitro and in vivo. In conclusion, the present study demonstrated for the first time that trans-splicing was exploited as a strategy for the repair of mutant p53 transcripts, which revealed that trans-splicing would be developed as a new therapeutic approach for human colorectal cancers carrying p53 mutation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.